Endobronchial epstein-barr virus associated post-transplant lymphoproliferative disorder in hematopoietic stem cell transplantation

Clinical Medicine: Case Reports

Volumn 2009, Issue 2, 2009, Pages 11-15

  Feuillet, S ^a   Meignin, V ^a   Briere J ^a   Brice, P ^a   Rocha, V ^a   Socie G ^a   Tazi, A ^a   Bergeron, Anne ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bronchoscopy; Endobronchial patterns; Epstein barr virus; Hematopoietic stem cell transplantation; Post transplant lymphoproliferative disorders

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; RITUXIMAB;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATELECTASIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRONCHOSCOPY; BRONCHUS BIOPSY; BRONCHUS TUMOR; CANCER RELAPSE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG RESPONSE; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; FEVER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOPROLIFERATIVE DISEASE; MALE; POLYMERASE CHAIN REACTION; REMISSION; VIRUS INFECTION;

EID: 63349084325     PISSN: None     EISSN: 11786450     Source Type: Journal    
DOI: 10.4137/ccrep.s2084     Document Type: Article

References (20)

1. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood. 2006;107:862-9.
2. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-16.
3. Hauke RJ, Greiner TC, Smir BN, et al. Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant. 1998;21:1271-4.
4. Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med. 2005;26:631-45.
5. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogenic SCT. Bone Marrow Transplant. 2008;42:181-6.
6. Halkos ME, Miller JI, Mann KP, et al. Thoracic presentations of posttransplant lymphoproliferative disorders. Chest. 2004;126:2013-20.
7. Shoji N, Ohyashiki JH, Suzuki A, et al. Multiple pulmonary nodules caused by B-cell post-transplant lymphoproliferative disorder after bone marrow transplantation: monitoring Epstein-Barr virus viral load. Jpn J Clin Oncol. 2003;33:408-12.
8. Tolar J, Coad JE, Ramsay NK, et al. Lymphoproliferative disorder presenting as pulmonary nodules after bone marrow transplantation. Bone Marrow Transplant. 2001;28:808-10.
9. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999;68:1517-25.
10. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest. 1999;116:1273-7.
11. Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest. 2003;124:1242-9.
12. Lones MA, Kirov I, Said JW, et al. Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient. Bone Marrow Transplant. 2000;26:1021-4.
13. Shepherd JD, Gascoyne RD, Barnett MJ, et al. Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant. 1995;15: 639-41.
14. Hou HA, Yao M, Tang JL, et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant: 2008 Oct 6. [Epub ahead of print] doi. 10.1038.
15. Kunitomi A, Arima N, Ishikawa T. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab. Haematologica. 2007;92:e49-52.
16. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6:569-76.
17. Trappe R, Riess H, Babel N, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation. 2007;83:912-8.
18. Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev. 2004;18:193-209.
19. Legere BM, Saad CP, Mehta AC. Endobronchial post-transplant lymphoproliferative disorder and its management with photodynamic therapy: a case report. J Heart Lung Transplant. 2003;22:474-7.
20. Barker JN, Martin PL, Coad JE, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant. 2001;7:395-399.18.